BackOrient Pharma , Ltd. Overview
Orient Pharma Co., Ltd.

Orient Pharma , Ltd. Return on Equity

Valuation check: 4166.TWO's ROE is 9.67%, below the sector sector average of 10.27%.

Get informed when a big investor buys or sells

+ Follow

ROE

9.67%

Return on Equity

9.67%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Orient Pharma , Ltd. (4166.TWO) FAQ

Orient Pharma , Ltd. (4166.TWO) currently reports a ROE of 9.67%. That is below the sector sector average of 10.27%. Use the charts on this page to explore Orient Pharma , Ltd.'s ROE history and peer comparisons.

Orient Pharma , Ltd.'s ROE of 9.67% is lower than the its sector sector average of 10.27%. That is roughly 5.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Orient Pharma , Ltd.'s current 9.67% should be judged against industry norms (sector average: 10.27%) and against 4166.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 9.67%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 10.27%. From there, open related valuation or income-statement pages for Orient Pharma , Ltd., and consider following 4166.TWO for alerts when major investors trade the stock.

Questions & Answers